Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

CAPS Rating: 2 out of 5

The Company is engaged in the discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules.

Recs

0
Player Avatar calor (< 20) Submitted: 4/6/2011 1:17:57 AM : Outperform Start Price: $8.48 ARIA Score: +97.98

I have followed ARIA during 8 years, the research and technology in progress is very sophisticated, it will treat tumors that currently have no therapies and very poor prognosis. It will eventually take over by MERCK(MRK) which currently has a deal in one of the leading drugs to co-promote. Annual projected income in just this product is upwards of 1 Billion, profits to be shared. More to come from this great biotech company

Report this Post Reply

Featured Broker Partners


Advertisement